PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.

Full Article